Colorectal Cancer Study

A study exploring a potential new combination treatment in people who are diagnosed with unresectable advanced, or metastatic (e.g., has spread to other parts of the body) colorectal adenocarcinoma.

Now Enrolling

Tagmokitug (CHS-114): Phase 1b, Cohort D: Advanced Solid Tumors

Trial ID: NCT06657144

About This Study

TREGCHECK™ 102

Colorectal Cancer Study
Clinical Trial ID: NCT06657144

This study is evaluating the investigational drug called tagmokitug (CHS-114) in combination with toripalimab for individuals with unresectable, advanced, or metastatic colorectal adenocarcinoma.

This combination is investigational and not approved to treat any disease.

Who Can Participate?

Is this trial right for you?

You may be eligible for the TREGCHECK™ 102 (Phase 1b, Cohort D) clinical trial if:

You have a diagnosis of colorectal adenocarcinoma

Your cancer has spread to the surrounding region or has metastasized

Your cancer may have worsened after certain treatments

Your cancer cannot be surgically removed

Review Eligibility Criteria

Only the study team can determine if you meet all eligibility criteria. For more information on eligibility criteria, please visit https://www.clinicaltrials.gov/study/NCT06657144#participation-criteria or contact one of the study sites. Your doctor may also be able to help you.

Frequently Asked Questions

Answers to Some Questions You May Have About the TREGCHECK™ 102 Clinical Trial (Phase 1b, Cohort D)

What is informed consent?

An Informed Consent Form helps you understand all the facts about your treatment.

What is this study about?

TREGCHECK™ 102 (Phase 1b, Cohort D) is testing a combination of drugs including a new research drug called tagmokitug (CHS-114), along with toripalimab to see if they may work in people with advanced unresectable colorectal cancer.

What is tagmokitug (CHS-114)

Tagmokitug (CHS-114) is a type of drug called immunotherapy. Tagmokitug (CHS-114) is an investigational drug and is not approved by the FDA.

What is being tested?

Tagmokitug (CHS-114) is being tested to see if it may help the body’s own immune system fight cancer when administered in combination with another drug called toripalimab. Toripalimab is also an immunotherapy drug. While toripalimab has not been approved to treat colorectal cancer, it has been approved by the FDA to treat nasopharyngeal cancer.

How do I sign up for the study?

First, talk to your doctor to see if this study may be right for you. You can also learn more about clinical trials by visiting a website like ClinicalTrials.gov or click here to find participating study locations near you. Each study location has a website or phone number where you can ask questions. A nurse or study doctor will help you understand what’s needed to join.

How long will I be in this study?

The treatment may be for up to two and a half years with follow-up visits of up to three years.

Are there any disadvantages to taking part in this study?

The disadvantages of taking part in this study are those associated with treatment such as side effects and follow-up as well as the time and inconvenience to you of attending the research site for further visits.

Will I have to pay for anything?

You will not need to pay for study drug tagmokitug (CHS-114), toripalimab, medical visits, laboratory tests, or any imaging and procedures that may be done as part of the study.

Will I be compensated?

You may be compensated for your time depending on the total number of study visits that you complete or reimbursed for the costs associated with your travel to the study site.

What to Expect

Guiding You Through Each Step with Care

If you qualify and choose to participate in our TREGCHECK™ 102 clinical trial, here’s what the process typically involves:

1

Screening

After you sign an Informed Consent Form, the study team will evaluate you to confirm that you can participate in the study.

2

Treatment

You will receive tagmokitug (CHS-114) and toripalimab over a period of two-and-a-half years.

3

Follow-Up

Your health and disease status will be monitored for several years following treatment.

TREGCHECK™ 102 Trial Sites

Finding a location that works for you

This study is offered at select research sites. Find your nearest location below to learn more.

Study site locations are subject to change. Please visit ClinicalTrials.gov for the most up to date list of locations.

Patient Support

Patient Advocacy Organizations

VV-00367 03/2026